about
Histone deacetylases as new therapy targets for platinum-resistant epithelial ovarian cancerEndometriosis and ovarian cancer: links, risks, and challenges facedOvca1 regulates cell proliferation, embryonic development, and tumorigenesisDendrosomal nanocurcumin and p53 overexpression synergistically trigger apoptosis in glioblastoma cellsDynamics of p53 and NF-κB regulation in response to DNA damage and identification of target proteins suitable for therapeutic intervention.p53 autoantibodies as potential detection and prognostic biomarkers in serous ovarian cancer.Genomic aberrations in borderline ovarian tumors.NSC109268 potentiates cisplatin-induced cell death in a p53-independent manner.The molecular pathogenesis of hereditary ovarian carcinoma: alterations in the tubal epithelium of women with BRCA1 and BRCA2 mutations.Histone h1.3 suppresses h19 noncoding RNA expression and cell growth of ovarian cancer cellsMucinous tumors of the ovary: current thoughts on diagnosis and managementUnmasking the complexities of mucinous ovarian carcinoma.Expression levels of p53 and p73 isoforms in stage I and stage III ovarian cancer.The mTORC2 component rictor contributes to cisplatin resistance in human ovarian cancer cells.Microarray enriched gene rankSodium arsenite ± hyperthermia sensitizes p53-expressing human ovarian cancer cells to cisplatin by modulating platinum-DNA damage responsesAlterations in nuclear pore architecture allow cancer cell entry into or exit from drug-resistant dormancy.Molecular mechanisms and biological plausibility underlying the malignant transformation of endometriosis: a critical analysis.Morphological and molecular basis of ovarian serous carcinoma.The endometriotic tissue lining the internal surface of endometrioma: hormonal, genetic, epigenetic status, and gene expression profile.Neurofibromin 1 (NF1) defects are common in human ovarian serous carcinomas and co-occur with TP53 mutationsResistance to chemotherapy in cancer: a complex and integrated cellular response.Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications.Biomarker discovery in ovarian cancer.Tumor spreading to the contralateral ovary in bilateral ovarian carcinoma is a late event in clonal evolution.LncRNAs expression profiling in normal ovary, benign ovarian cyst and malignant epithelial ovarian cancer.Histological profile and age at diagnosis of breast and ovarian tumors: A register-based study in Espirito Santo, Brazil.Ovarian cancer in endometriosis: clinical and molecular aspects.Essential Roles of E3 Ubiquitin Ligases in p53 Regulation.Changes in O-Linked N-Acetylglucosamine (O-GlcNAc) Homeostasis Activate the p53 Pathway in Ovarian Cancer Cells.TP53 Mutations in Breast and Ovarian Cancer.Inhibition of p53 represses E-cadherin expression by increasing DNA methyltransferase-1 and promoter methylation in serous borderline ovarian tumor cells.Cancer Markers Selection Using Network-Based Cox Regression: A Methodological and Computational Practice.Inhibition of p53 induces invasion of serous borderline ovarian tumor cells by accentuating PI3K/Akt-mediated suppression of E-cadherin.Potential impact of (rs 4645878) BAX promoter -248G>A and (rs 1042522) TP53 72Arg>pro polymorphisms on epithelial ovarian cancer patients.The p53 mutation spectrum in hepatocellular carcinoma from Guangxi, China : role of chronic hepatitis B virus infection and aflatoxin B1 exposure.Effect of the codon 72 polymorphism (c.215G>C, p.Arg72Pro) in combination with somatic sequence variants in the TP53 gene on survival in patients with advanced ovarian carcinoma.Cancer predisposition in mice deficient for the metastasis-associated Mts1(S100A4) gene.Multifocal intrafollicular granulosa cell tumor of the ovary associated with an unusual germline p53 mutation.Granulosa Cell-Specific Brca1 Loss Alone or Combined with Trp53 Haploinsufficiency and Transgenic FSH Expression Fails to Induce Ovarian Tumors.
P2860
Q26777453-E2E77BA9-B1D7-4549-8D5D-A57E4E9B618AQ27003273-AB9E1C8D-9017-403E-94C9-74B4651C092FQ28586049-DF75D343-E252-4B2D-807B-00B8689844E2Q29248936-1D01D0EB-230D-416B-BC5C-43572959A96AQ31090728-CEAE85A7-FB5C-4BE6-9442-D7C3A3245D02Q33725961-7B586691-63E2-4746-8A7C-E8BBF3D0487CQ33728834-5941D9AC-DC8A-4571-B478-50D0AC2CB53AQ33930946-6FEA5082-98C5-43CF-AB0A-E5AD67439430Q34288214-2E730EA9-F187-4D60-A01C-71492E67CFE4Q34518349-AA2CEB8C-E2D9-4478-9EE5-ADB57375EA8EQ34667838-DE601D2F-68A1-4865-B23F-933AC48C7C43Q34695404-F42894D5-8C6A-4400-87AE-94118F88583FQ34856099-A1DC72F5-FE8D-4F92-889F-DC8A4613C41FQ35005636-53BB1ACE-E842-4C46-9A88-6AAC4968E74BQ35008782-556022F0-5DB2-42EB-8626-2EF0138ADB5CQ35892810-6B1D6351-DB80-452F-9E73-3DA02CEAB382Q35917703-732611F4-D320-4728-94ED-8AE35360F5A0Q36261402-DE3873FE-0F6F-4B70-AFAA-1CE3F497A879Q36681565-C43840A7-649F-45E3-A5CA-7AD941ED0084Q36742613-0F12A5A0-E305-4BBD-894C-D09E0BC41300Q36982106-CF30BC4B-A013-453F-91D7-D07CC0CA5CC4Q37079652-3509AC86-90CF-4654-A11F-0E17E2F35C7DQ37101060-4C4CF812-2D87-47E2-A544-459366073BD9Q37346072-89708909-931A-4B09-A34D-6C417E3FB55CQ37347191-250A3351-B612-4FA9-8B9C-9A809F2D3BF7Q37492937-D9884402-2D5E-4E4F-951E-F6B3AF548ADEQ37641094-84C31E6D-55E9-44B8-A4D5-1F8490FAF441Q37645709-396D9508-07C7-4706-9738-22F11AE58B7AQ37691041-6EB2F1F8-63C6-4DBD-AAD4-4643FD82A946Q38758695-8367B09A-60C0-4BB6-B59B-A0C75267AF45Q38999130-591928EC-9E3C-44D3-BEC5-E39679ADF4F8Q39561459-48503320-7520-4630-B6D8-EFB0AC3900B4Q39631395-19811958-720A-489A-AEDC-B5A5DA71C0EDQ39640387-D2E6D380-290D-40AC-AC29-809AE0711EEFQ41549687-B0587EC3-48D6-4D69-8976-70FECC7DA1FCQ42241369-27DEEB29-A79C-4115-A3CB-9BC0E3320624Q44955068-99302A85-DA90-4795-A179-4387235E37B1Q47677925-ED01526B-63AC-44D7-95FA-A2FD3AAE2951Q47791696-28008651-CFE6-4877-B1A1-9BA7C2BCC2D8Q50980879-3F303BE4-6FA0-4750-8241-8614B6930921
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մարտին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
TP53 and ovarian cancer.
@ast
TP53 and ovarian cancer.
@en
type
label
TP53 and ovarian cancer.
@ast
TP53 and ovarian cancer.
@en
prefLabel
TP53 and ovarian cancer.
@ast
TP53 and ovarian cancer.
@en
P356
P1433
P1476
TP53 and ovarian cancer.
@en
P2093
Els M J J Berns
Monique Schuijer
P304
P356
10.1002/HUMU.10181
P577
2003-03-01T00:00:00Z